Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Stage IA Esophageal Cancer
Stage IA Gastric Cancer
Stage IB Esophageal Cancer
Stage IIB Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage IIA Gastric Cancer
Stage IIIA Gastric Cancer

Interventions: Biological: bevacizumab
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2010-10-01

Last Posted Date: 2022-09-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 20

Registration Number: NCT01212822

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer

Phase 2

Conditions: Rectal Cancer

Interventions: Drug: fluorouracil, oxaliplatin
Drug: fluorouracil

First Posted Date: 2010-09-29

Last Posted Date: 2015-05-22

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 495

Registration Number: NCT01211210

Locations: 🇨🇳
Gastrointestinal Hospital, Sun Yatsen University, Guangzhou, Guangdong, China

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer
Colon Cancer
Metastasis
Adenocarcinoma

First Posted Date: 2010-09-22

Last Posted Date: 2019-04-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT01206530

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: pralatrexate
Drug: fluorouracil
Other: laboratory biomarker analysis
Genetic: DNA analysis
Other: high performance liquid chromatography
Genetic: polymerase chain reaction
Genetic: nucleic acid sequencing
Other: pharmacological study
Other: pharmacogenomic studies
Genetic: polymorphism analysis

First Posted Date: 2010-09-21

Last Posted Date: 2023-12-26

Lead Sponsor: University of Nebraska

Target Recruit Count: 29

Registration Number: NCT01206465

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2010-09-20

Last Posted Date: 2014-07-08

Lead Sponsor: Cardiff University

Target Recruit Count: 111

Registration Number: NCT01205711

Locations: 🇬🇧
Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Centre for Cancer Research and Cell Biology at Queen's University Belfast, Belfast, Northern Ireland, United Kingdom

and more 1 locations

Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Recurrent Rectal Cancer
Stage IV Rectal Cancer
Recurrent Colon Cancer
Stage IV Colon Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: fluorouracil
Biological: bevacizumab
Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Other: laboratory biomarker analysis

First Posted Date: 2010-09-20

Last Posted Date: 2015-06-08

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 3

Registration Number: NCT01205022

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IV Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: leucovorin calcium
Biological: bevacizumab
Dietary Supplement: cholecalciferol
Drug: fluorouracil
Drug: oxaliplatin
Other: pharmacological study

First Posted Date: 2010-09-10

Last Posted Date: 2014-07-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01198548

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

Phase 1

Terminated

Conditions: Mucinous Adenocarcinoma of the Rectum
Stage IIA Rectal Cancer
Stage IIB Rectal Cancer
Stage IIC Rectal Cancer
Stage IIIB Rectal Cancer
Stage IIIC Rectal Cancer

Interventions: Drug: paricalcitol
Radiation: radiation therapy
Other: laboratory biomarker analysis
Drug: fluorouracil

First Posted Date: 2010-09-09

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2

Registration Number: NCT01197664

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

A Study in Second Line Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Biological: Placebo
Biological: Ramucirumab
Drug: Irinotecan
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2010-08-18

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1072

Registration Number: NCT01183780

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Lenalidomide
Drug: Bevacizumab
Drug: Sorafenib
Drug: Temsirolimus
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-fluorouracil

First Posted Date: 2010-08-17

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT01183663

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy